Campiotti, Leonardo <br/><br/>
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  05 2017 
 - 48-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis; Review; Systematic Review 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2017.02.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Drug Substitution<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Remission Induction